Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Petrol Diesel Prices
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
India

SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI

SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
Written by Siddhant Pandey
Jan 03, 2021, 11:58 am 3 min read
SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI

Two COVID-19 vaccines, Covishield and COVAXIN, have been granted emergency approval for use in India, the Drugs Controller General of India (DCGI) Dr. VG Somani said on Sunday. Covishield has been developed by AstraZeneca and Oxford University, and manufactured by Pune-based Serum Institute of India (SII), while COVAXIN has been developed indigenously by the Hyderabad-based Bharat Biotech. Here are more details.

Quote
2 vaccines approved for 'restricted use in emergency situation'

While addressing a press conference, Dr. Somani said, "After adequate examination, the CDCSO has decided to accept the recommendations of the expert committee, and accordingly, the vaccines of Serum Institute of India and Bharat Biotech are being approved for restricted use in an emergency situation." "Permission is being granted to Cadila Healthcare for the conduct of Phase III clinical trials in India," he added.

Recent news
Earlier, concerns were raised about nod to vaccines

Earlier on Saturday, the Subject Expert Committee (SEC) of the Central Drugs Standards Control Organisation (CDSCO) had recommended the grant of emergency approval to COVAXIN. A day earlier, the same panel had recommended emergency approval for Covishield. The nod to COVAXIN was deemed controversial as the recommendation came despite a lack of Phase III trial data indicating the vaccine's efficacy.

Information
Covishield 95% effective if doses given 3 months apart: SII

Both Covishield and COVAXIN are two-dose vaccines. SII CEO Adar Poonawalla had said last week that Covishield is "90-95% effective" if the two doses are given two-three months apart. Earlier, he had said that India has 40-50 million doses already stockpiled.

Quote
'Vaccines are 110% safe,' says DCGI

Addressing criticism over vaccine approval, the DCGI told reporters, "We would never approve (a vaccine) if there are any safety concerns... The vaccines are 110% safe." "There are some mild side-effects, such as pain on the injection site, mild fever, and allergy. But these are common for every vaccine," he said, declaring the claims of impotency being a side-effect "absolute rubbish."

PM statement
'Decisive turning point,' says PM Modi

In a series of tweets, Prime Minister Narendra Modi said the development marked a "decisive turning point to strengthen a spirited fight." "Congratulations India. Congratulations to our hardworking scientists and innovators," he wrote. The PM further said that India will remain "eternally grateful" to the doctors, medical staff, scientists, police personnel, sanitation workers, and all "corona warriors" at the frontlines of the pandemic.

Outbreak
How bad is the outbreak in India?

As of Sunday morning, India has reported 1,03,23,965 COVID-19 cases, with a spike of 18,177 new infections reported in the past 24 hours. The total cases include 2,47,220 active infections, while 99,27,310 people have recovered. The death toll has risen to 1,49,435 with 217 new fatalities over a 24-hour period. India is the world's second worst-hit country in the outbreak after the United States.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
Oxford University
United States of America
Drugs Controller General of India
Coronavirus
Serum Institute of India
Related
Latest
IPL 2022 Eliminator: KL Rahul elects to field
IPL 2022 Eliminator: KL Rahul elects to field Sports
'The Gray Man': Russo Brothers tease spin-off featuring Dhanush's character
'The Gray Man': Russo Brothers tease spin-off featuring Dhanush's character Entertainment
2022 French Open: Sasnovich ousts Raducanu; early exit for Sakkari
2022 French Open: Sasnovich ousts Raducanu; early exit for Sakkari Sports
RedmiBook Pro 14, 15 introduced with Ryzen 6000 series chipsets
RedmiBook Pro 14, 15 introduced with Ryzen 6000 series chipsets Technology
Nivin Pauly's 'Padavettu' gears up for Onam release
Nivin Pauly's 'Padavettu' gears up for Onam release Entertainment
Oxford University
COVID-19 vaccine maker Professor Sarah Gilbert honored with Barbie doll
COVID-19 vaccine maker Professor Sarah Gilbert honored with Barbie doll World
AstraZeneca vaccine's single dose reduces death risk by 80%: Data
AstraZeneca vaccine's single dose reduces death risk by 80%: Data World
#OxfordUniversity racism row: India to raise the issue when required
#OxfordUniversity racism row: India to raise the issue when required India
Five killed in Serum Institute fire; Maharashtra government orders probe
Five killed in Serum Institute fire; Maharashtra government orders probe India
Maldives to become first foreign country to receive Covishield doses
Maldives to become first foreign country to receive Covishield doses World
More News
United States of America
A look at deadliest school shootings; Texas leads the way
A look at deadliest school shootings; Texas leads the way World
Monkeypox: Maharashtra, Tamil Nadu, Rajasthan prepare to fight against virus
Monkeypox: Maharashtra, Tamil Nadu, Rajasthan prepare to fight against virus India
PM Modi meets Japanese IT giant head, discusses investment opportunities
PM Modi meets Japanese IT giant head, discusses investment opportunities World
Afghan women TV hosts cover faces after Taliban's diktat
Afghan women TV hosts cover faces after Taliban's diktat World
'Concerned' WHO expects more monkeypox cases globally
'Concerned' WHO expects more monkeypox cases globally World
More News
Drugs Controller General of India
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
Biological E's Corbevax vaccine approved for children aged 12-18 years
Biological E's Corbevax vaccine approved for children aged 12-18 years India
COVAXIN, Covishield will now be available in hospitals and clinics
COVAXIN, Covishield will now be available in hospitals and clinics India
New anti-COVID drug may cost up to Rs. 3,000: Report
New anti-COVID drug may cost up to Rs. 3,000: Report India
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
Serum Institute of India
India inching closer to launching its first dengue vaccine
India inching closer to launching its first dengue vaccine Technology
COVID-19 vaccine precautionary dose service charge capped at Rs. 150
COVID-19 vaccine precautionary dose service charge capped at Rs. 150 India
DCGI approves emergency use of Covovax in children above 12
DCGI approves emergency use of Covovax in children above 12 India
Govt panel okays phase-3 trials of Covovax as booster dose
Govt panel okays phase-3 trials of Covovax as booster dose India
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla India
More News
Related
India's drug regulator approves study on mixing Covishield, COVAXIN jabs
India's drug regulator approves study on mixing Covishield, COVAXIN jabs India
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN India
Expert panel says no to Covovax's children trials in India
Expert panel says no to Covovax's children trials in India India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022